Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals

Clinical and Vaccine Immunology

Volumn 15, Issue 2, 2008, Pages 284-292

  Connolly, Nancy C ^a   Whiteside, Theresa L ^b   Wilson, Cara ^a   Kondragunta, Venkatswarlu ^c   Rinaldo, Charles R ^a,d   Riddler, Sharon A ^a,d,e  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GAG PROTEIN; GAMMA INTERFERON; HLA A2 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS 1 PEPTIDE; MATRIX PROTEIN; PEPTIDE; POL PROTEIN; SYNTHETIC PEPTIDE; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EPITOPE;

ADULT; AGED; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CULTURE MEDIUM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOTHERAPY; INFLUENZA VIRUS A; LEUKAPHERESIS; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIREMIA; BIOSYNTHESIS; DENDRITIC CELL; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTI-HIV AGENTS; CELLS, CULTURED; DENDRITIC CELLS; EPITOPES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY; INFLUENZA A VIRUS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; LEUKAPHERESIS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; VIRAL PROTEINS;

EID: 40449119721     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00221-07     Document Type: Article

References (32)

1. Altfeld, M. A., B. Livingston, N. Reshamwala, P. T. Nguyen, M. M. Addo, A. Shea, M. Newman, J. Fikes, J. Sidney, P. Wentworth, R. Chesnut, R. L. Eldridge, E. S. Rosenberg, G. K. Robbins, C. Brander, P. E. Sax, S. Boswell, T. Flynn, S. Buchbinder, P. J. Goulder, B. D. Walker, A. Sette, and S. A.Kalams. 2001. Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif. J. Virol. 75:1301-1311.
2. Asai, T., W. J. Storkus, and T. L. Whiteside. 2000. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. Clin. Diagn. Lab. Immunol. 7:145-154.
3. Autran, B., G. Carcelain, T. S. Li, C. Blanc, D. Mathez, R. Tubiana, C. Katlama, P. Debre, and J. Leibowitch. 1997. Positive effects of combined antiretroviral therapy on CD4 + T cell homeostasis and function in advanced HIV disease. Science 277:112-116.
4. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:6103-6110.
5. Connolly, N., S. A. Riddler, C. R. Rinaldo, C. C. Wilson, S. Ferrone, J. Stanson, and T. L. Whiteside. 2004. Dendritic cell vaccination: a novel therapy for HIV-1-infected subjects. Pre-clinical characterization of peptide-loaded, autologous dendritic cells for use as a therapeutic vaccine. Abstr. XV Int. AIDS Conf., Bangkok, Thailand, abstr. no. WePeB5683.
6. Connolly, N., B. Colleton, and C. R. Rinaldo. 2007. Treating HIV-1 infection with dendritic cells. Curr. Opin. Mol. Ther. 9:353-363.
7. Connolly, N., S. Riddler, J. Stanson, W. Gooding, C. r. Rinaldo, S. Ferrone, and T. W. Whiteside. 2007. Evaluating DC function in chronically HIV-1 infected subjects: levels of antigen processing machinery components in monocyte-derived dendritic cells generated for therapeutic vaccines. AIDS 21:1683-1692.
8. Davey, R. T., Jr., N. Bhat, C. Yoder, T. W. Chun, J. A. Metcalf, R. Dewar, V. Natarajan, R. A. Lempicki, J. W. Adelsberger, K. D. Miller, J. A. Kovacs, M. A. Polis, R. E. Walker, J. Falloon, H. Masur, D. Gee, M. Baseler, D. S. Dimitrov, A. S. Fauci, and H. C. Lane. 1999. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA 96:15109-15114.
9. Garcia, F., M. Lejeune, N. Climent, C. Gil, J. Alcami, V. Morente, L. Alos, A. Ruiz, J. Setoain, E. Fumero, P. Castro, A. Lopez, A. Cruceta, C. Piera, E. Florence, A. Pereira, A. Libois, N. Gonzalez, M. Guila, M. Caballero, F. Lomena, J. Joseph, J. M. Miro, T. Pumarola, M. Plana, J. M. Gatell, and T. Gallart. 2005. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J. Infect. Dis. 191:1680-1685.
10. Goulder, P. J., R. E. Phillips, R. A. Colbert, S. McAdam, G. Ogg, M. A. Nowak, P. Giangrande, G. Luzzi, B. Morgan, A. Edwards, A. J. McMichael, and S. Rowland-Jones. 1997. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3:212-217.
11. Hilkens, C. M., P. Kalinski, M. de Boer, and M. L. Kapsenberg. 1997. Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 90:1920-1926.
12. Hoffmann, T. K., J. Muller-Berqhaus, R. L. Ferris, J. T. Johnson, W. J. Storkus, and T. L. Whiteside. 2002. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 8:1787-1793.
13. Hoffmann, T. K., N. Meidenbauer, J. Muller-Berghaus, W. J. Storkus, and T. L. Whiteside. 2001. Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cells. J. Immunother. 24:162-171.
14. Ide, F., T. Nakamura, M. Tomizawa, A. Kawana-Tachikawa, T. Odawara, N. Hosoya, and A. Iwamoto. 2006. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial. J. Med. Virol. 78:711-718.
15. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
16. Lichtner, M., C. Maranon, P. O. Vidalain, O. Azocar, D. Hanau, P. Lebon, M. Burgard, C. Rouzioux, V. Vullo, H. Yagita, C. Rabourdin-Combe, C. Servet, and A. Hosmalin. 2004. HIV type 1-infected dendritic cells induce apoptotic death in infected and uninfected primary CD4 T lymphocytes. AIDS Res. Hum. Retroviruses 20:175-182.
17. + lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J. Virol. 75:10187- 10199.
18. Lu, W., L. C. Arraes, W. T. Ferreira, and J. M. Andrieu. 2004. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 10:1359-1365.
19. Ogg, G. S., X. Jin, S. Bonhoeffer, P. R. Dunbar, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones, V. Cerundolo, A. Hurley, M. Markowitz, D. D. Ho, D. F. Nixon, and A. J. McMichael. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:2103-2106.
20. Oxenius, A., D. A. Price, H. F. Gunthard, S. J. Dawson, C. Fagard, L. Perrin, M. Fischer, R. Weber, M. Plana, F. Garcia, B. Hirschel, A. McLean, and R E. Phillips. 2002. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc. Natl. Acad. Sci. USA 99:13747-13752.
21. Palella, F. J., Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, S. D. Holmberg, et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
22. Powderly, W. G., A. Landay, and M. M. Lederman. 1998. Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA 280:72-77.
23. Rinaldo, C, X. L. Huang, Z. F. Fan, M. Ding, L. Beltz, A. Logar, D. Panicali, G. Mazzara, J. Liebmann, M. Cottrill, et al. 1995. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 69:5838-5842.
24. Rosenberg, E. S., J. M. Billingsley, A. M. Caliendo, S. L. Boswell, P. E. Sax, S. A. Kalams, and B. D. Walker. 1997. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278:1447-1450.
25. Ruiz, L., J. Martinez-Picado, J. Romeu, R. Paredes, M. K. Zayat, S. Marfil, E. Negredo, G. Sirera, C. Tural, and B. Clotet. 2000. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 14:397-403.
26. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1109-1118.
27. Schmitz, J. E., M. J. Kuroda, S. Santra, V. G. Sasseville, M. A. Simon, M. A. Lifton, P. Racz, K. Tenner-Racz, M. Dalesandro, B. J. Scallon, J. Ghrayeb, M. A. Forman, D. C. Montefiori, E. P. Rieber, N. L. Letvin, and K. A. Reimann. 1999. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283:857-860.
28. Schultes, B. C, and T. L. Whiteside. 2003. Monitoring of immune responses to CA125 with an IFN-gamma ELISPOT assay. J. Immunol. Methods 279: 1-15.
29. Sinkovics, J. G., and J. C. Horvath. 2000. Vaccination against human cancer. Int. J. Oncol. 16:81-96.
30. Wang, B., W. B. Dyer, J. J. Zaunders, M. Mikhail, J. S. Sullivan, L. Williams, D. N. Haddad, G. Harris, J. A. Holt, D. A. Cooper, M. Miranda-Saksena, R. Boadle, A. D. Kelleher, and N. K. Saksena. 2002. Comprehensive analyses of a unique HIV-1-infected nonprogressor reveal a complex association of immunobiological mechanisms in the context of replication-incompetent infection. Virology 304:246-264.
31. Whiteside, T. L., Y. Zhao, T. Tsukishiro, E. M. Elder, W. Gooding, and J. Baar. 2003. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin. Cancer Res. 9:641-649.
32. Wierecky, J., M. Mueller, and P. Brossart. 2006. Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol. Immunother. 55:63-67.